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Abstract: Background: The zinc transporter Zip7 modulates zinc flux and controls cell signaling
molecules associated with glucose metabolism in skeletal muscle. The present study evaluated the
role of Zip7 in cell signaling pathways involved in insulin-resistant skeletal muscle and mice fed
a high-fat diet. Methods: Insulin-resistant skeletal muscle cells were prepared by treatment with an
inhibitor of the insulin receptor, HNMPA-(AM)3 or palmitate, and Zip7 was analyzed along with
pAkt, pTyrosine and Glut4. Similarly, mice fed normal chow (NC) or a high-fat diet (HFD) were also
analyzed for protein expression of Glut4 and Zip7. An overexpression system for Zip7 was utilized
to determine the action of this zinc transporter on several genes implicated in insulin signaling
and glucose control. Results: We identified that Zip7 is upregulated by glucose in normal skeletal
muscle cells and downregulated in insulin-resistant skeletal muscle. We also observed (as expected)
a decrease in pAkt and Glut4 in the insulin-resistant skeletal muscle cells. The overexpression of Zip7
in skeletal muscle cells led to the modulation of key genes involved in the insulin signaling axis and
glucose metabolism including Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg. In an in vivo mouse
model, we identified a reduction in Glut4 and Zip7 in the skeletal muscle of mice fed a HFD compared
to NC controls. Conclusions: These data suggest that Zip7 plays a role in skeletal muscle insulin
signaling and is downregulated in an insulin-resistant, and HFD state. Understanding the molecular
mechanisms of Zip7 action will provide novel opportunities to target this transporter therapeutically
for the treatment of insulin resistance and type 2 diabetes.
Keywords: zinc; zinc transporter; Zip7; insulin signaling pathway; high-fat diet; skeletal muscle
1. Introduction
It was estimated in 2013 that 382 million people were affected by diabetes and this number is
expected to increase to 592 million by 2035 [1]. This rapid escalation in diabetes can be attributed to
rapid economic developments and lifestyle changes associated with reduced physical activity and
an increase in the consumption of high calorie diets, resulting in a higher obesity prevalence [2].
Adipose tissue dysfunction is one mechanism responsible for systemic metabolic complications, such
as type-2 diabetes (T2D) [3,4]. T2D is characterized by insulin resistance in major peripheral metabolic
tissues including adipose tissue, liver and skeletal muscle. While most obese individuals do not
become diabetic even in the face of a high degree of insulin resistance, most patients with T2D are
obese [5]. Thus, in addition to insulin resistance, compromised pancreatic β-cell function leads to
increased blood glucose and contributes to hyperglycemia and overt T2D [6].
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Research on T2D has revealed a role for the physiological importance of zinc and the proteins
that transport this metal ion in cells (zinc transporters) in diseases associated with abnormal cell
signaling pathways and metabolism such as insulin resistance (IR) and T2D [7]. Zinc is a vital trace
element that is present in organs, tissues, fluids and secretions and functions as a critical cofactor
in an extensive number of biological signaling pathways as a catalytic, structural or regulatory
component [8]. The storage, release and distribution of cellular zinc are regulated by a family of
zinc transporter proteins and metallothioneins. In mammals, there are 24 zinc transporter proteins
divided into two families. These are the zinc eﬄux (Slc30/ZnT, members 1–10) and the zinc influx
(Slc39/ZIP, members 1–14) proteins [9]. The ZnT members function to transport zinc from the cell or
into subcellular organelles when cytoplasmic zinc is high. In contrast, the ZIP members function to
transport zinc into the cell when zinc in the cytosol is low or depleted [10].
Emerging research has highlighted key roles for zinc transporter ZIP7 in signaling pathways.
ZIP7 is located in the endoplasmic reticulum (ER) membrane and it is regulated in response to
phosphorylation by casein kinase II (CK2), an enzyme that promotes cell division [11]. ZIP7 is
a gatekeeper of cytosolic zinc release from subcellular organelles including the ER and Golgi
apparatus [12]. It has been demonstrated that genetic ablation of ZIP7 resulted in reduced cytosolic zinc
levels, and abnormalities in cell proliferation and ER function in human osteosarcoma cell lines [13].
Similarly, dysfunctional ZIP7 caused proliferation of the tamoxifen-resistant MCF-7 breast cancer
phenotype [14]. Recent data on zinc transporters also suggests that Zip7 is implicated in glucose
metabolism and glycemic control in skeletal muscle cells [15]. The ablation of Zip7 in skeletal muscle
cells resulted in a substantial reduction in several genes and proteins involved in glucose homeostasis.
These included the phosphorylation of Akt, the insulin receptor (Ir), insulin receptor substrates 1 and 2
(Irs1 and Irs2), the glucose transporter Glut4, and glycogen branching enzyme (Gbe). Similarly, studies
identified a redistribution of cellular ER zinc in hyperglycemic rat heart cells that involved changes in
Zip7 protein and Zip7 phosphorylation [16]. Given the role of Zip7 in regulating zinc flux and the
activation of key cell signaling molecules associated with glucose metabolism, we propose that this
transporter controls cell signaling pathways involved in glucose metabolism in skeletal muscle.
2. Materials and Methods
2.1. Cell Culture
Mouse C2C12 cells were obtained from Professor Steve Rattigan, Menzies Institute for Medical
Research, Hobart, Australia. C2C12 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher, Victoria, Australia) medium that contained 10% fetal calf serum (FCS) and 100 U/mL
penicillin/streptomycin (Thermo Fisher) and were maintained at 37 ◦C and 5% CO2 in a humidified
atmosphere. C2C12 cells were differentiated into myotubes by the addition of media containing
2% horse serum (Thermo Fisher) for seventy-two hours. The cells were then exposed to serum-free
conditions for three hours prior to the different treatments as outlined below.
2.2. Protein Extraction
Whole cell protein lysates were prepared in RIPA Lysis buffer in the presence of protease and
protein phosphatase inhibitors (Thermo Fisher) as previously described [17]. Briefly, whole cell lysates
were vortexed every 10 min for 1 h on ice and centrifuged at 15,000 rpm for 5 min. The protein
concentrations of the supernatants were determined by a BCA assay kit as per manufacturer’s
instructions (Thermo Fisher).
2.3. RNA Extraction
Total RNA was extracted using the Qiagen RNeasy Mini Kit as per manufacturer’s instructions
(Qiagen, Victoria, Australia). Briefly, cells were lysed in RLT Buffer, placed directly into a QIAshedder
spin column and centrifuged for 2 min. Lysates were then passed through a RNeasy spin column and
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purified by adding RW1 and RPE buffer. The purified RNA was eluted in RNAse-free water and total
RNA concentration was determined by UV spectrometry.
2.4. cDNA Synthesis
Complementary DNA (cDNA) was synthesized from extracted total RNA using a High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher, Victoria, Australia) and using random hexamers
according to the manufacturer’s instructions. Briefly, 10 µL cDNA reverse-transcription mix was added
to 10 µL genomic DNA elimination mix and incubated at 42 ◦C for 15 min. The reaction was stopped
by incubating the samples at 95 ◦C for 5 min. The resulting reverse transcription products were stored
at −20 ◦C until use.
2.5. Mice and Diets
The experimental procedures for all animal work has been previously described and the mice
used in these experiments represent a sub group of a previously published cohort of animals [18].
All experiments involving the use of animals for research were approved by the Alfred Medical
Research Education Precinct Animal Ethics Committee and were conducted in accordance with the
National Health and Medical Research Council of Australia guidelines. Ethics number E/1255/2012/B.
Mice (six mice per group) were fed either a normal chow (NC) diet (14.3 MJ/kg, 76% of kJ from
carbohydrate, 5% fat, 19% protein) or a high-fat diet (HFD), (19 MJ/kg, 36% of kJ from carbohydrate,
43% fat [42.7% saturated, 35.1% monounsaturated and 21.7% polyunsaturated fatty acids] and,
21% protein), Specialty Feeds, Glen Forrest, Western Australia, Australia). During the experiment,
the animals were given their prescribed diet and water ad libitum, except for fasting periods before
a glucose tolerance test and were housed at 22 ◦C on a 12-h light/dark cycle.
2.6. Body Composition Analysis
Body mass was measured using standard laboratory scales (Mettler Toledo, Greifensee, Switzerland).
Lean and fat mass was measured using a 4-in-1 EchoMRI (Houston, TX, USA).
2.7. Oral Glucose Tolerance Test
Mice were fasted for 6 h and subsequently received an oral gavage of 2 g glucose/kg lean body
mass (25% w/v glucose solution). An oral glucose tolerance test (OGTT) was performed and glucose
levels were measured from tail tip blood at 0, 15, 30, 45, 60, 90 and 120 mins.
2.8. Mouse Tissue Collection and Protein Extraction
Mice were sacrificed by sodium pentobarbital overdose. Skeletal muscle quadriceps were used
for analysis. Skeletal muscles used for protein analysis were frozen on dry ice and stored at −80 ◦C
until analysis. A protease inhibitor cocktail was added to the CelLytic MT (Mammalian Tissue
Lysis/Extraction Reagent, Sigma) reagent and a ratio of tissue to CelLytic MT reagent of 1:20 was used
for tissue protein extraction. Samples were then transferred to a pre-chilled microhomogenizer and
tissues were homogenized. The lysed samples were centrifuged for 10 min at 12,000–20,000× g to
pellet the tissue debris. The protein- containing supernatants were transferred to a chilled test tube
and stored at −80 ◦C. Protein concentrations of the supernatants were determined using the BCA assay
kit as per manufacturer’s instructions (Thermo Fisher).
2.9. Fatty Acid Preparation and Cell Culture Treatment
Palmitate was prepared as previously described [19]. Briefly, fatty acid was mixed with ethanol to
a final concentration of 100 mM. Then the mixture was sonicated on ice at 200W with 10-sec bursts,
3-sec off pulses until the mixture became a milky homogenous solution. Prepared fatty acid stock
was kept at 4 ◦C and protected from light. For fatty acid treatment, the fatty acid stock solution was
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added to the cell culture medium containing 2% horse serum at 60 ◦C to a final concentration as stated.
For the control, the same amount of ethanol was added to the cell culture medium containing 2%
horse serum. Cells were cultured with increasing concentrations of palmitate-containing media for
24 h followed by 10 nM insulin treatment for 30 min prior to cell lysate harvest. Following treatment,
whole cell lysates were prepared and immunoblot analysis was performed on pAkt, Zip7, glucose
transporter 4 (Glut4), phospho-tyrosine and Gapdh.
2.10. Cell Viability Assay [1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan] Assay
Cell viability was measured using the MTT (3-(4,5)-dimethylthiahiazo(−z-y1)-3,5-
diphenytetrazoliumromid) assay as per manufacturer’s instructions (Thermo Fisher). Briefly, C2C12
skeletal muscle cells were seeded at a density of 2 × 104 cells/well in a 96-well plate. Following
C2C12 differentiation the cells were treated with varying concentrations of palmitate (as described
in the results) for 24 h. Then 15 µL of 5 mg/mL MTT was added to each well. Following a 4 h
incubation at 37 ◦C, the produced formazan was solubilized in 150 µL dimethyl sulfoxide (DMSO).
The absorbance was measured at 490 nm using a microplate reader (TECAN infinite M200 PRO,
Männedorf, Switzerland).
2.11. Insulin Receptor Inhibition
Insulin receptor tyrosine kinase activity is inhibited by 50 µM insulin receptor tyrosine kinase
inhibitor hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester (HNMPA-(AM)3)
after 1 h. It suppresses the activation of pAkt after 30 min of insulin treatment [17]. C2C12 skeletal
muscle cells were treated with the insulin receptor inhibitor [HNMPA-(AM)3] (Abcam, Victoria,
Australia) for 1 h at 0, 25 and 50 µM. This was followed by treating the C2C12 cells with 10 nM insulin
for 30 min. Following treatment, whole cell protein lysates were extracted and immunoblot analysis
was performed on pAkt, Zip7, glucose transporter 4 (Glut4) and Gapdh.
2.12. Western Blotting
Tissue or cell-extracted proteins (20 µg) were electrophoresed using 4–15% SDS-polyacrylamide
gels (Bio-Rad, New South Wales, Australia) and immunoblotted using semi-dry electrophoresis blotting
system. Phosphorylated Akt (1:5000), Zip7 (1:1000) or Glut4 (1:1000) (Cell Signaling Technology,
Beverly, MA, USA) primary antibodies were used for immunoblotting. Antibodies were detected with
HRP-linked secondary antibodies (1:5000) (Cell Signaling Technology, USA). Then, membranes were
stripped with Restore Plus Western Blot Stripping Buffer (Thermo Fisher) and reprobed for the related
housekeeping gene (Gapdh 1:2000 or total Akt 1:5000, Cell Signaling Technology, USA). Proteins were
visualized with SuperSignal West Femto Kit (Thermo Fisher) and imaged using an Odyssey infrared
imaging system (LiCor, Millennium Science, Victoria, Australia). Relative band density was quantified
using Image J software. Representative immunoblots are provided. Experiments were repeated three
times and statistical analysis was performed on the signal intensity of the protein of interest relative to
the house keeping gene on all protein bands from each of the experiments.
2.13. Zip7 Overexpression
To determine the role of Zip7 in modulating cellular pathways, a plasmid-based system was
constructed that overexpressed the Zip7 protein (Origene, Rockville, MD, USA, Clone ID MR216531;
plasmid cytomegalovirus, pCMV-Zip7). The vector was transformed into high-efficiency bacterial cells
and plasmid DNA was isolated using an ISOLATE Plasmid Kit. The bacterial transformation was
performed by heat-shock at 42 ◦C for 30 s as described by the manufacturer’s instructions (Thermo
Fisher). The transformed bacteria were plated onto LB agar plates containing appropriate antibiotics
and incubated overnight at 37 ◦C. Bacterial colonies were harvested and plasmids isolated using
an ISOLATE II plasmid midi kit as per the manufacturer’s instructions (Bioline, New South Wales,
Australia). Restriction digest analysis using the enzymes Sgf1 and and Mlu1 was used to determine
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the correct insertion of the Zip7 gene from the plasmid. Zip7 containing plasmids were transfected
into skeletal muscle cells using Lipofectamine 3000 reagent (Thermo Fisher) as per manufacturer’s
instructions. Briefly, skeletal muscle cells were cultured as previously described in 6-well dishes.
Once the cells had reached 70% confluence, approximately 1 µg of pCMV-Zip7 (and pCMV empty
vector) was mixed with the Lipofectamine 3000 in DMEM and placed on the cells. After 24 h the cells
were harvested for RNA and protein. The quality and quantity of RNA were assessed by nucleic acid
spectrometry (Bio-Rad) and the measurement of optical density at 260 and 280 nm.
2.14. Quantitative Real-Time PCR (qPCR)
To determine whether Zip7 is overexpressed in skeletal muscle cells, qPCR was performed as
previously described [15]. qPCR was performed using 20 ng of cDNA template with 2 x Sensi Fast
Sybr (Bioline) as per manufacturer’s instructions. The relative level of target gene expression was
normalized to eukaryotic elongation factor 2 (Eef2). Primers to amplify the Zip7 sequence were
designed using PrimerFind (NCBI: https://www.ncbi.nlm.nih.gov). Sequences of the primers were as
follows: Zip7 (forward: 5′- CGC ATG CCT TGG AAC CTC AT- 3′; Reverse: 5′- GGC GAC AAT CCC
ACT GAG AA-3′), Eef2 (Forward: 5′- CAC AAT CAA ATC CAC CGC CAT-3′; Reverse: 5′- TGG CCT
GGA GAG TCG ATG A- 3′) (Integrated DNA Technologies, Singapore Science Park II, Singapore).
RT2 qPCR Primer Assay for Mouse Slc2a4, (Qiagen), was used to amplify the Glut4 sequence.
2.15. Insulin Signaling Pathway Array
Insulin Signaling Pathway Array (SABiosciences, Qiagen) was utilized to detect the expression of
84 genes implicated in the insulin signaling pathway. cDNA from the control (empty vector; pCMV)
and pCMV-Zip7 transfected C2C12 cells was assayed across the array. Real-time PCR was performed
to analyze the expression of a focused panel of genes related to insulin-responsiveness and results
were analyzed using GeneGlobe Data Analysis Center (Qiagen, Australia).
2.16. Data Analysis
Results are presented as means ± SDs. Statistical comparisons were performed using Student’s
t-test (Prism GraphPad, version 8, San Diego, CA, USA) for mRNA expression and protein analysis.
A significant effect was demonstrated at p < 0.05. For mouse studies, differences between normal chow
(NC) and high-fat diet (HFD) (diet effect) were analyzed by a paired t-test. For the OGGT, two-way
analysis of variance (ANOVA) with a post-hoc analysis (Bonferroni) was used to detect the effect of diet
on glucose clearance. Analysis was performed by Prism GraphPad (version 8). A P value less than
0.05 was considered statistically significant.
3. Results
3.1. Glucose Regulates Zip7 Expression in C2C12 Skeletal Muscle Cells
Previously we have shown that reduced Zip7 in C2C12 skeletal muscle cells led to a significant
decrease in the phosphorylation of Akt, reduced Glut4 expression and compromised insulin-mediated
glycogen synthesis [15]. Accordingly, we wanted to test whether glucose could regulate Zip7 in C2C12
skeletal muscle cells to establish a role for this transporter in glycemic control. Previous studies have
reported that Zip7 is upregulated by glucose in rat cardiomyocytes [16] and mouse pancreatic islets [20].
Accordingly, treatment of C2C12 cells with 0, 10 and 25 mM glucose for 2 h resulted in a robust increase
in the protein expression of Zip7 (Figure 1a,b).
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Figure 1. Analysis of Zip7 in mouse skeletal muscle cells treated with glucose. (a) Increasing
concentrations of glucose (0, 10 and 25 mM) were added to C2C12 cells over 24 h. G pdh w used as
a in er al loading control and levels of Zip7 w re normalized to Gapdh. Represent tive im ge of
three indepe dent western blot assays that were perform on three independe t reatments (n = 3).
(b) Densitometry graphs for Zip7 from thre independent data westerns blots. * = p < 0.05.
3.2. The Expression of Zip7 and Glut4 Is Suppressed in Insulin-Resistant C2C12 Cells Treated with Either
an Insulin Receptor Inhibitor Hnmpa-(Am)3 or Palmitate
Given that Zip7 could be regulated by glucose in C2C12 skeletal muscle cells, we decided to
perform several studies to recapitulate a compromised glucose state in skeletal muscle by creating
insulin-resistant C2C12 cells. To recapitulate an insulin-resistant state in skeletal muscle we utilized two
experimental procedures: (1) an inhibitor of the insulin receptor and, (2) palmitate treatment [19,21,22].
Initially we tested the ability of the insulin receptor inhibitor HNMPA-(AM)3 to inhibit the insulin
signaling pathway by measuring the downstream target of the insulin receptor, Akt. It has been
previously shown that 50 µM of HNMPA-(AM)3 is sufficient to inhibit insulin-induced pAkt in C2C12
cells [19]. Accordingly, 50 µM of HNMPA-(AM)3 was sufficient to inhibit the insulin-dependent
activation of pAkt in C2C12 skeletal muscle cells (Figure 2a,b). We also assayed the levels of Zip7 and
Glut4 in the HNMPA-(AM)3 treated C2C12 cells and identified a significant reduction in the levels of
these proteins (Figure 2a,c,d).
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It has been shown previously that saturated fatty acid palmitate reduces insulin sensitivity and
induces insulin resistance in skeletal muscle [18]. In this experiment, the inhibitory effect of palmitate
on the insulin signaling pathway in C2C12 myotubes was tested. Initially we aimed to test the viability
of the C2C12 cells following palmitate treatment. The result of the MTT assay showed that 0.3 mM
of palmitate did not significantly suppress C2C12 cell viability (Figure 3a), while at the same time,
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it suppressed insulin-stimulated phosphorylation of Akt (Figure 3b,c). Accordingly, we chose 0.3 mM
of palmate as the highest concentration of this fatty acid in the following experiments.
To determine the effect of palmitate treatment on Zip7 we assayed the level of Zip7 protein in
palmitate-treated C2C12 cells. The expression level of Zip7 protein were reduced when treated with
increasing concentrations of palmitate (Figure 3b,d). We also observed a reduction in pAkt in the
presence of palmitate as previously described [19]. Glut4 was also reduced in the presence of increasing
palmitate concentrations (Figure 3b,e). We also tested the ability of palmitate to reduce the levels of
phospho-tyrosine, a key amino acid involved in cellular signal transduction. Following palmitate
treatment, the levels of phospho-tyrosine were also reduced (Figure 3b,f). These results indicate that
palmitate treatment was sufficient to induce an insulin-resistant state in C2C12 skeletal muscle cells (as
evidence by the reduction in pAkt and phospho-tyrosine).
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assay in C2C12 cells treated with increasing concentrations of palmitate. Concentrations of palmitate
are 0, 0.2, 0.3 and 0.4 mM (white bars); 0.5, 0.6. 0.8 and 1 mM (black bars). Cell viability was performed
three times (n = 3). (b) Palmitate-induced insulin resistance in C2C12 cells. Cells were treated with 0,
0.1, 0.2 and 0.3 mM palmitate over 24 h, then stimulated with 10 nM insulin for 30 min before harvesting
total protein. Phosphorylated Akt (Ser473), Zip7, Glut4 and phosphor-tyrosine were immunoprobed
by western blotting. Gapdh was used as an internal control. Three independent western blots on three
independent treatments were performed (n = 3). (c–f). Densitometry graphs for pAkt, Zip7, Glut4,
and pTyrosine, respectively from three independent data westerns blots * = p < 0.05, ** = p < 0.01,
*** = p < 0.001.
3.3. Testing the Function of ZIP7 in Controlling Genes Involved in Insulin Signaling
The above studies suggest that Zip7 is involved in metabolic processes that could enhance cell
signaling pathways associated with glucose metabolism. Accordingly, we wanted to test whether Zip7
could cti ate gen s implica ed in insulin s gna ing and glucose homeostasis. Initially w overexpr ssed
Zip7 in C2C12 skeletal muscle cells utilizing an overexpression plasmid pCMV (Figure 4). We observed
a signific nt increase in pCMV-Zip7 mRNA compared to pCMV control (Figure 4a). Similarly,
we observed a sig ificant increase in pCMV-Zip7 protein c mpared to pCMV control (Figure 4b,c).
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Figure 4. Overexpression of Zip7 in C2C12 skeletal muscle cells. (a) Quantitative real-time polymerase
chain reaction (PCR) for the overexpression of Zip7 RNA in pCMV versus pCMV-Zip7. (b) Western
blot for pCMV-Zip7 protein. Gapdh was used as a loading control. (c) Densitometry results from
the western blot data pCMV versus pCMV-Zip7. The experiments were perfor ed three times and
statistical significance compared ZIP-7 over-expressed group to the control. *** = p < 0.001.
To further identify the effect of pCMV-Zip7 overexpression on insulin signaling, we used an insulin
signaling pathway array, which has the targeted expression of eighty-four genes involved in insulin
signaling and glucose metabolism. The genes were selected based on a commercially available insulin
signaling array (SABiosciences, Qiagen) and focused cellular pathways. We tested the pCMV-Zip7
overexpression plasmid to target the expression of genes on this array. Following transfection of the
pCMV-Zip7 overexpression plasmid and control empty vector (pCMV) in C2C12 cells, total RNA
was extracted, and cDNA synthesis performed. Changes in the expression of all genes on the array
following pCMV-Zip7 overexpression transfection are presented as (1) the gene name, (2) fold up or
down regulation, and (3) the p-value (Table 1). Although we identified several genes with fold-change
expression greater than the statistically significant highlighted genes in Table 1 below (in bold), these
did not reach significance and did not meet the stringent data normalization processes (GeneGlobe
Data Analysis Center Qiagen).
Table 1. Insulin signaling gene array.
Gene Name Fold–Up orDownregulation p–value
Insulin Receptor–Associated Proteins
Eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1) −5.42 0.109812
Insulin−like growth factor 2 (Igf2) −2.51 0.119985
Growth factor receptor bound protein 2 (Grb2) −1.81 0.044301
Fibroblast growth factor receptor substrate 3 (Frs3) −1.78 0.342511
Sorbin and SH3 domain containing 1 (Sorbs1) −1.57 0.261979
Protein tyrosine phosphatase, receptor type, F (Ptprf) −1.49 0.376424
Grow h factor receptor bound protein 2−associated protein 1 (Gab1) −1.48 0.237770
Non−catalytic region of tyrosine kinase adaptor protein 1 (Nck1) −1.24 0.479138
Fibroblast growth factor receptor substrate 2 (Frs2) −1.21 0.514579
Protein tyrosine phosphatase, non−receptor type 1 (Ptpn1) −1.19 0.481621
Heat shock protein 90 alpha (cytosolic), class B member 1 (Hsp90ab1) 1.04 0.965684
src homology 2 domain−containing transforming protein C1 (Shc1) .13 0.659820
Protein phosphatase 1 catalytic subunit alpha (Ppp1ca) 1.15 0.595936
Casitas B−lineage lymphoma (Cb1) 1.15 0.759472
Insulin receptor substrate 1 (Irs1) 1.47 0.435010
Insulin−like growth factor I receptor (Igfr) 1.54 0.241275
Insulin receptor substrate 2 (Irs2) 1.67 0.240410
Prolactin (Prl) 1.82 0.518438
Insulin 1 (Ins1) 2.04 0.401028
Insulin−like growth factor binding protein 1 (Igfbp1) 2.14 0.391212
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Table 1. Cont.
Gene Name Fold–Up orDownregulation p–value
Neuropeptide Y (Npy) 2.60 0.057738
Docking protein 1 (Dok1) 2.91 0.103312
Docking protein 3 (Dok3) 3.30 0.315765
Growth factor receptor bound protein 10 (Grb10) 3.75 0.140065
Insulin−like 3 (InsI3) 4.33 0.287920
Thyroglobulin (Tg) 5.53 0.179122
Docking protein 2 (Dok2) 21.79 0.031048
PI3 Kinase Signaling
Thymoma viral proto−oncogene 3 (Akt3) −2.16 0.019032
Phosphoinositide−3−kinase regulatory subunit 1 (Pik3r1) −1.57 0.350159
Thymoma viral proto−oncogene 2 (Akt2) −1.46 0.384953
Protein kinase C, gamma (Prkcg) −1.42 0.281971
Eukaryotic translation initiation factor 2B, subunit 1 (alpha) (Eif2b1) −1.39 0.219592
Phosphatidylinositol−4,5−bisphosphate 3−kinase catalytic subunit alpha (Pik3ca) −1.38 0.333187
Phosphatidylinositol−4,5−bisphosphate 3−kinase catalytic subunit beta (Pik3cb) −1.30 0.444354
3−phosphoinositide dependent protein kinase 1 (Pdpk1) −1.15 0.751995
Protein kinase C, iota (Prkci) −1.14 0.707935
Mechanistic target of rapamycin kinase (Mtor) 1.08 0.874784
BCL2−like 1 (Bcl2l1) 1.21 0.631682
Phosphoinositide−3−kinase regulatory subunit 2 (Pik3r2) 1.22 0.653162
Adrenergic receptor, alpha 1d (Adra1d) 1.25 0.391856
Thymoma viral proto−oncogene 1 (Akt1) 1.36 0.241863
Dual specificity phosphatase 14 (Dusp14) 1.42 0.465154
Protein kinase C, zeta (Prkcz) 2.00 0.327070
Serine peptidase inhibitor, clade E, member 1 (Serpine 1) 2.09 0.131939
MAP Kinase Signaling
Related RAS viral (r−ras) oncogene 2 (Rras2) −1.86 0.075688
Braf transforming gene (Braf) −1.78 0.127855
Related RAS viral (r−ras) oncogene (Rras) −1.63 0.070002
Araf proto−oncogene, serine/threonine kinase (Araf) −1.40 0.331800
SOS Ras/Rac guanine nucleotide exchange factor 1 (Sos1) −1.21 0.477393
Excision repair cross−complementing rodent repair deficiency, complementation
group 1 (Ercc1) −1.02 0.884782
v−raf−leukemia viral oncogene 1 (raf1) 1.03 0.834133
Uncoupling protein 1 (mitochondrial, proton carrier) (Ucp1) 1.26 0.433977
Mitogen−activated protein kinase kinase 1 (Map2k1) 1.43 0.244012
Mitogen−activated protein kinase 1 (Mapk1) 1.82 0.134200
Kruppel−like factor 10 (Klf10) 2.12 0.143675
Nitric oxide synthase 2, inducible (Nos2) 2.21 0.030364
Harvey rat sarcoma virus oncogene (Hras) 2.30 0.027193
Ribosomal protein S6 kinase polypeptide 1 (Rps6ka1) 2.93 0.286011
FBJ osteosarcoma oncogene (Fos) 4.42 0.014490
Carbohydrate Metabolism
Phosphoenolpyruvate carboxykinase 2 (mitochondrial) (Pck2) −2.73 0.046319
Glucuronidase, beta (Gusb) −2.44 0.057494
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Table 1. Cont.
Gene Name Fold–Up orDownregulation p–value
Pyruvate kinase liver (Pkl) −2.00 0.361565
AE binding protein 1 (Aebp1) −1.36 0.346200
acyl−Coenzyme A oxidase 1, palmitoyl (Acox1) −1.23 0.517860
Hexokinase 2 (Hk2) 1.06 0.892955
Glycogen synthase kinase 3 beta (Gsk3b) 1.04 0.908617
Glyceraldehyde−3−phosphate dehydrogenase (Gapdh) 1.15 0.642638
Glucose−6−phosphatase, catalytic (G6pc) 1.22 0.432012
Glycerol−3−phosphate dehydrogenase 1 (Gpd1) 1.43 0.434684
Solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1) 1.50 0.246541
Glucokinase (Gck) 1.96 0.316235
Fructose bisphosphatase 1 (Fbp1) 3.40 0.315244
Glucose−6−phosphatase, catalytic, 2 (G6pc2) 4.71 0.189288
Lipid Metabolism
Complement factor D (adipsin) (Cfd) −3.66 0.370569
Peroxisome proliferator activated receptor gamma (Pparg) −3.31 0.007128
Sterol regulatory element binding transcription factor 1 (Srebf1) −1.59 0.041612
Resistin (Retn) −1.71 0.786857
Low density lipoprotein receptor (Ldlr) −1.11 0.938288
Leptin (Lep) 1.31 0.490170
Solute carrier family 27 (fatty acid transporter), member 4 (Slc27a4) 1.33 0.350357
Cell Growth and Differentiation
Kirsten rat sarcoma viral oncogene homolog (Kras) 2.12 0.025606
CCAAT/enhancer binding protein (C/EBP), alpha (Cebpa) −1.41 0.700291
Vascular endothelial growth factor A (Vegfa) −1.14 0.660055
CAP, adenylate cyclase−associated protein 1 (Cap1) −1.13 0.673316
Jun proto−oncogene (Jun) 1.02 0.996474
Beta−2 microglobulin (B2m) 1.13 0.700177
Actin, beta (Actb) 1.28 0.577259
CCAAT/enhancer binding protein (C/EBP), beta (Cebpb) 2.33 0.145381
Note: Genes are listed by specific pathways: insulin receptor and associated proteins, PI3 kinase signaling, MAP
kinase signaling, carbohydrate metabolism, lipid metabolism, and cell growth and differentiation. Please also note
that several genes can belong to multiple pathways. The fold change for each gene within the pathway is shown
initially as the highest value for the downregulation (a negative symbol) followed by a sequential increase in values
into the positive range.
Representative graphs are given for the genes that were significantly changed due to the over
expression of pCMV-Zip7. These include Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg,
(Figure 5a–h).
3.4. The Expression of Zip7 and Glut4 Is Reduced in the Skeletal Muscle of Mice Fed a High-Fat Diet
The results above suggest that Zip7 has a role in modulating genes involved in glucose metabolism
and is reduced in an insulin-resistant state when treated pharmacologically or with fatty acids.
This suggests that Zip7 could be regulated by changes in fatty acids or a high-fat diet, for example.
To determine if Zip7 is modulated by a high-fat diet we performed experiments on C57BL/6J mice
consuming a normal chow (NC) or high-fat diet (HFD) for 10 weeks. As expected on the HFD, body
weight, fat mass and body fat percentages were increased compared to the NC-fed mice while lean
mass remained unchanged (Figure 6a–d). Next, we performed an oral glucose tolerance test (OGTT)
to assess insulin-stimulated glucose clearance. While blood glucose decreased over a 120-min time
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course in both NC and HFD cohorts, there was an overall dietary effect on glucose clearance in the
HFD mice versus the NC control (Figure 6e).
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overexpression. Genes are (a) Akt3, (b) Dok2, (c) Fos, (d) Hras, (e) Kras, (f) Nos2, (g) Pck2, (h) Pparg.
Control = pCMV empty vector. Zip7 = overexpression pCMV-Zip7. * p < 0.05, ** p < 0.01.
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Figure 6. Characteristics of mice fed a normal chow (NC) diet or a high-fat diet (HFD) for 10 weeks.
(a) body weight (g), (b) fat mass (g), (c) lean mass (g), (e) fat mass (%), (f) plasma glucose levels over
120 min following an oral gavage of 2 g glucose/kg lean body mass (25% w/v glucose solution). Unpaired
t-test was used for the NC versus the HFD comparisons (a–d) and a two-way repeated measure ANOVA
was used for the OGTT (e). Graphs indicate mean ± SD. * = p < 0.05. *** p < 000.1.
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To determine the protein expression of Zip7 in NC versus HFD-fed mice, we performed western
blots on proteins extracted from quadricep skeletal muscle tissue from both cohorts. We observed
a significant decrease in the expression of Zip7 and Glut4 in the HFD mice groups relative to control
mice (Figure 7a,b).
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Figure 7. Analysis of Zip7 in mouse skeletal muscle tissues in NC versus HFD mice. Gapdh was used
as an internal loading control and levels of Zip7 were normalized to Gapdh. (a) Western blot for Zip7
in NC versus HFD. (b) Densitometry of the western blot results. The experiments were performed on
six animals per group (n = 6) and statistical significance was compared between the HFD to the NC
mice group. * = p < 0.05.
We also measured the protein levels of Glut4 in the NC versus the HFD mice. We observed
a significant reduction in the protein levels of Glut4 in the HFD mice when compared to the NC mice
(Figure 8a,b).
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Figure 8. Analysis of Glut4 in NC versus HFD mouse skeletal muscle tissues. Gapdh was used as an
internal loading control and levels of Glut4 were normalized to Gapdh. (a) Western blot for Glut4 in
NC mice versus HFD. (b) Densitometry of the western blot results. The experiments were performed
on six animals per group (n = 6) and statistical significance was compared between the HFD to the NC
mice group. ** = p < 0.01.
4. Discussion
We have previously demonstrated the effect of zinc as an essential trace element implicated
in the insulin signaling pathway [17]. However, its mechanism of action in the insulin signaling
pathway and glucose uptake has not been determined. Insulin resistance, a hallmark of T2D [23],
is characterized by compromised insulin-mediated activation of the PI3K/Akt pathway regulating
glucose uptake via Glut4 transporters [24]. Skeletal muscle is the major site of peripheral insulin
resistance of which much of the complexity of this disorder remains undefined, including the role of
zinc and zinc transporter Zip7 in insulin signaling and glucose metabolism. Previous investigations
showed that zinc has insulin mimetic activity leading to increased total glucose consumption [17].
Glucose transporters are important proteins that regulate glucose uptake through cellular membranes.
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In this regard, Glut4 facilitates the transport of glucose in skeletal muscle [25]. Glut4 translocation to
the cell membrane from specialized storage vesicles in the cytosol by insulin is a rate-limiting step of
glucose disposal [26]. Accordingly, treatment of L6 rat skeletal muscle cells with zinc induced Glut4
translocation in a dose-dependent manner [26]. These studies showed that zinc exerted insulin-like
effects by phosphorylation of Akt and subsequent mobilization of glut4.
Several studies have shown that disturbances in zinc transporter function and consequently zinc
signaling lead to cellular and physiological disturbances. For example, zinc transporter ZnT8-deficient
mice exposed to a high-fat diet develop severe insulin resistance and obesity [27]. Similarly,
Zip13-deficient mice have enhanced beige adipocyte production and energy expenditure and this was
concomitant with resistance to HFD-induced obesity, and improved glucose and insulin tolerance [28].
Other studies have shown that ZIP7 (and ZIP6) play an important role in regulating zinc homeostasis in
MIN6 pancreatic beta cells [29]. These studies identified a compensatory increase in the expression of
ZIP7 in the presence of a targeted ZIP6 knockdown. It was suggested that ZIP6 and ZIP7 transporters
orchestrate cytosolic zinc flux by increasing extracellular zinc uptake or by releasing ER-stored zinc
into the cytosol when required. This is supported by studies where ZIP7 knockdown in human
osteosarcoma (MG-63) cells exhibited an increase in ER zinc and a decrease in cytosolic zinc [13].
Moreover, other studies have identified a dual role for ZIP7 and ZnT7 in cardiomyocytes [16]. Here it
was identified that changes in the expression of ZIP7 and ZnT7 induces ER stress through the loss
of ER zinc during hyperglycemic conditions. These authors also suggest that perturbations in the
expression of ZIP7 and ZnT7 may lead to decompartmentalization of zinc across the ER and therefore
lead to persistent ER stress.
In the context of Zip7, ablation of this transporter in mouse skeletal muscle cells resulted in
reduced Glut4 protein and a reduction in insulin-stimulated glycogen synthesis [15]. To expand on this
study, we examined the protein levels of both Zip7 and Glut4 in an in vitro insulin-resistant skeletal
muscle cell model and an in vivo skeletal muscle of mice fed normal chow (NC) versus a high-fat
diet (HFD).
First, we treated C2C12 skeletal muscle mouse cells with glucose to recapitulate hyperglycemic
conditions and measured the protein levels of Zip7. We observed a significant increase in the protein
levels of Zip7 in cells treated with increasing concentrations of glucose. This result is supported by
studies showing high glucose induces the expression of Zip7 mRNA in mouse pancreatic islets [20]
and Zip7 mRNA and protein in rat cardiomyocytes [16].
Second, we aimed to recapitulate an in vitro insulin-resistance cell culture model and investigate
the protein levels of Glut4 and Zip7. C2C12 skeletal muscle cells were treated with HNMPA-(AM)3,
an inhibitor of insulin receptor tyrosine kinase activity, and palmitate. HNMPA-(AM)3 abolished the
expression of insulin-induced pAkt and is supported by previous studies [17,30,31]. We observed
a clear reduction in Zip7 and Glut4 protein upon treatment with HNMPA-(AM)3. To our knowledge no
data exists showing insulin receptor inhibition action on Zip7 expression. Similarly, palmitate-induced
insulin resistance in C2C12 skeletal muscle cells was comparable with the insulin receptor inhibition
study. Excessive plasma free fatty acids are associated with insulin resistance in both diabetic and
non-diabetic subjects [19]. Palmitate plays a critical role in the initiation and development of insulin
resistance as exposure of C2C12 cells to palmitate suppressed insulin-stimulated Akt1 phosphorylation
and glucose uptake [19]. It was observed that palmitate treatment reduced insulin-induced Akt
phosphorylation that is consistent with an insulin resistant state [21]. Moreover, the protein expression
of Zip7 and Glut4 were reduced by palmitate and by HNMPA(AM)3. We also detected a decrease in the
phospho-tyrosine expression in palmitate-treated C2C12 cells. These data suggest that Zip7 is involved
in the insulin signaling pathway and glucose metabolism. While it is unclear how Zip7 contributes
to the control of these pathways, there is some evidence on the potential mechanisms. For example,
studies in C2C12 mouse skeletal muscle cells identified that ablation of Zip7 resulted in the modulation
of key genes implicated in glucose metabolism including those of glycolysis, gluconeogenesis, the
citric acid cycle, and glycogen metabolism [15]. Moreover, a reduction in the mRNA of the insulin
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receptor and insulin receptor substrates 1 and 2, Glut4 protein, pAkt and insulin-induced glycogen
synthesis was observed.
While these studies suggest that ZIP7 is associated with the insulin-signaling axis, how this
association occurs in unclear. The role of ZIP7 in initiating zinc flux from the ER into the cytosol poses
several questions, and are therefore limitations of this manuscript. For example, what are the cellular
concentrations of zinc during treatment with palmitate or HNMPA-(AM)3 in an insulin-resistant
state? To our knowledge, there are limited studies addressing the effect of fatty acids on cellular zinc
status. One study identified the fatty acids oleate, elaidate, stearate and palmitate increased zinc
concentrations in human macrophages, with elaidate having the greatest effect [32]. The authors suggest
the importance of this based on zinc being a major regulator of macrophage activity. Accordingly,
it will be important to determine cellular zinc status in insulin resistant skeletal muscle cells and
determine whether zinc signaling processes are compromised. Moreover, the role of ZIP7 in these
processes needs to be addressed. For example, if ZIP7 is reduced (or defective) in an insulin-resistant
state, what effect does this have in zinc mimetic activity, and glucose metabolism?
To further investigate effects of Zip7 on glucose metabolism and insulin signaling, we established
a Zip7 overexpression cell culture model. Previous studies identified that a reduction in Zip7 in skeletal
muscle cells resulted in changes in several genes involved in glucose metabolism [15]. To extend on
these studies, a plasmid-based system that overexpressed Zip7 was utilized to determine the ability of
this transporter to regulate genes involved in the insulin signaling pathway. These studies identified
significant changes in several genes including Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg.
It was observed that Akt3, Pck2, and Pparg were significantly downregulated in the
Zip7-overexpressing cells. The roles of Akt1 and Akt2 are well established in metabolism, however
there is less known about Akt3 [33]. It is suggested that Akt3 may play a role in defects in insulin
signaling that occur in insulin resistant states [34].
There are two Pck isoenzymes, phosphoenolpyruvate carboxykinase (PEPCK-C, cytoplasmic)
encoded by Pck1 and PEPCK-M (mitochondrial), encoded by Pck2 (mitochondrial). Although the role
of Pck1 has been extensively studied for its role in gluconeogenesis in the liver, Pck2 remains somewhat
unknown [35]. However, these data for Pck2 are consistent with previous studies where a reduction in
Zip7 mRNA led to an increase in this gene in C2C12 skeletal muscle cells [15].
Pparg (peroxisome proliferator activated receptor gamma) is a member of the nuclear hormone
superfamily of transcription factors that modulates genes involved in insulin signaling and lipid
metabolism [36]. While Pparg expression is low in skeletal muscle, C2C12 skeletal muscle cells
stably overexpressing Pparg resulted in increased glucose uptake and inhibition of Pparg expression
induced insulin resistance as determined by reduced deoxyglucose uptake [36]. In contrast, mice
heterozygous for Pparg+/- displayed greater insulin sensitivity than the wild-type animals [37] and
improved insulin resistance and obesity [38]. While these studies counter the current dogma on Pparg
action in metabolism, it is not clear why Pparg expression is reduced in our overexpression Zip7 studies.
A recent study identified Zip7 was upregulated by ethanol exposure in the livers of mice and this was
concomitant with a downregulation of anotherPpar family member, Ppara [39]. In C2C12 skeletal muscle
cells with an ablation of Pparg, it was identified that myogenic differentiation was compromised [40].
These studies suggest that Pparg is critical for the differentiation of skeletal muscle myoblast to
myotubes and perhaps Zip7 overexpression overrides the mechanism of Pparg-inhibitory effect on the
myogenic phenotype. Support for a Zip7-mediated role in promoting myogenic differentiation was
recently identified [41]. It was identified that zinc promotes myoblast proliferation and differentiation
of mature myotubes via Zip7 activation and the modulation of the Pi3k/Akt pathway in C2C12 skeletal
muscle cells.
We also observed significant upregulation of several genes in the Zip7 overexpression cell model
including Dok2, Fos, Hras, Kras, and Nos2. Dok2 (docking protein 2), along with its closest homologue
Dok1 work as adapter proteins that recruit and assemble multiple SH2-containing molecules including
p120 rasGAP and Nck [42]. There is little information on the role of Dok2 in skeletal muscle or
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insulin resistance, however experiments in mice lacking Dok1 or Dok2 showed enhanced expression
of Erk and Akt in myeloid cells [43]. Similarly, Dok2 significantly inhibited insulin-stimulated Akt
phosphorylation in COS7 cells and these authors suggested that Dok2 acts as an inhibitor of insulin
action [44]. These data therefore suggest that a reduction in Dok2 would have an enhancing effect on
insulin signaling.
c-Fos (FBJ osteosarcoma oncogene) is a protooncogene that dimerizes with c-Jun to form the
activator protein AP1 transcription complex [45]. C-Fos is implicated in several molecular mechanisms
that contribute to cellular processes including proliferation, differentiation, and apoptosis [46]. Recently,
parathyroid hormone-related peptide (PTHrP) induced c-Fos expression was significantly reduced in
Zip14-KO chondrocytes [47]. In chondrocyte differentiation, PTHrP induces phosphorylation of cAMP
and the subsequent regulation of c-Fos via phosphorylation of the cAMP response element-binding
protein (CREB) [47]. These studies suggest that Zip14 controls basal cAMP levels and its role may
provide a mechanism for the zinc-mediated regulation of endocrine signaling. Whether Zip7 controls
similar cAMP-mediated events (or whether Zip7 is regulated by cAMP) in skeletal muscle is yet to be
determined. Zinc itself affects a wide range of second messenger and signaling molecules including
Ca2+/calmodulin-dependent protein kinase II [48], Erk1/2, protein tyrosine phosphatase [17] and
cAMP-dependent protein kinase [49]. Future studies eliminating Zip7 in skeletal muscle for example
could provide valuable insight into the specific pathways controlled by Zip7-mediated zinc flux.
We also identified an increase in the expression of Hras (Harvey rat sarcoma virus oncogene) and
Kras (Kirsten rat sarcoma viral oncogene homolog) in the Zip7 overexpressing skeletal muscle cell
lines. Hras and Kras are canonical ras genes and are critical components of cell signaling pathways
that control proliferation, survival, and differentiation [50]. Ras activity induces Raf and subsequent
regulation of protein kinases Mek1/2 which phosphorylate ERK1/2. Mostly, the Ras/Raf/Mek/ERK
pathway is critical for cell proliferation and differentiation [51].
Finally, we assayed the expression levels of Zip7 in an in vivo HFD mouse model. Our results
revealed a decrease in the protein expression of both Zip7 and Glut4 in the skeletal muscle of HFD-fed
mice compared to the NC controls. While there are no other studies reporting this observation for
reduced Zip7 in skeletal muscle of HFD-fed mice, studies on obesity-associated inflammation in
mammary gland tissue found HFD mice had decreased levels of Zip7. These authors suggest that
inflammation in mammary tissue compromises lactation by mediating zinc retention in the endoplasmic
reticulum [52]. However, several studies have assessed zinc in the context of HFD. For example,
male rats fed a HFD had reduced weight gain, abdominal fat pads, plasma insulin levels, leptin and
triglycerides when supplemented with zinc [53]. Similarly, it was identified that zinc supplementation
improved glucose tolerance, HOMA-β, and glucose-stimulated insulin secretion in HFD mice by
enhancing pancreatic β-cell function [54]. In the context of plasma zinc levels, it has been identified
in obese humans and mice that leptin levels are increased with concomitant reduced plasma zinc
concentrations [55]. It was suggested by these authors that reduced zinc compromises several cell
signaling pathways that regulate inflammation and leptin. This is significant given that zinc-deficiency
is common in obese individuals [56].
While, the connection between Zip7 and Glut4 regulation is not known, our previous data
showing a reduction in Zip7 in C2C12 skeletal muscle cells led to a significant decrease in Glut4 protein
and compromised insulin-mediated glycogen synthesis [15] suggests that Zip7 might be involved
in skeletal muscle glycemic control. However, the mechanisms involved in these processes requires
further investigation.
The studies presented suggest that Zip7 has a role in modulating insulin-signaling molecules and
is reduced in an insulin-resistant state and in mice fed a HFD. While there were several changes in
genes associated with Zip7 overexpression, it is unknown how these changes contribute to insulin
signaling and cell signaling processes and affect glycemic control in skeletal muscle. Further studies are
required to delineate the molecular mechanisms of Zip7 action on cell signaling in both insulin-resistant
and diabetic in vitro and in vivo models.
Cells 2019, 8, 663 16 of 19
Author Contributions: Conceptualization, S.N., J.A., S.S.S. and S.M.; methodology, S.N., J.A., and S.S.S.; validation,
S.N., J.A., S.S., S.S.S., D.C.H., and S.M.; formal analysis, S.N., J.A., S.S., S.S.S., D.C.H., and S.M.; investigation, S.N.
and S.M.; resources, S.N., D.C.H., S.S.S., and S.M.; data curation, S.N and S.M.; writing—original draft preparation,
S.N and S.M.; writing—review and editing, S.N., J.A., S.S., S.S.S., D.C.H., and S.M.; visualization, S.N and S.M.;
supervision, S.M. and S.S.S.; project administration, S.N. and S.M.; funding acquisition, S.M.
Funding: This research was funded by Clifford Craig Foundation, grant number 184.
Acknowledgments: School of Health Sciences, College of Health and Medicine, University of Tasmania.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Guariguata, L.; Whiting, D.R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J.E. Global estimates of
diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014, 103, 137–149. [CrossRef]
[PubMed]
2. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global Prevalence of Diabetes: Estimates for the year 2000
and projections for 2030. Diabetes Care 2004, 27, 1047–1053. [CrossRef] [PubMed]
3. Hajer, G.R.; van Haeften, T.W.; Visseren, F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular
diseases. Eur. Heart J. 2008, 29, 2959–2971. [CrossRef] [PubMed]
4. Marcadenti, A.; Fuchs, S.C.; Moreira, L.B.; Wiehe, M.; Gus, M.; Fuchs, F.D. Accuracy of Anthropometric
Indexes of Obesity to Predict Diabetes Mellitus Type 2 among Men and Women with Hypertension. Am. J.
Hypertens. 2011, 24, 175–180. [CrossRef] [PubMed]
5. Berumen, J.; Orozco, L.; Betancourt-Cravioto, M.; Gallardo, H.; Zulueta, M.; Mendizabal, L.; Simon, L.;
Benuto, R.E.; Ramírez-Campos, E.; Marin, M. Influence of obesity, parental history of diabetes, and genes in
type 2 diabetes: A case-control study. Sci. Rep. 2019, 9, 2748. [CrossRef] [PubMed]
6. Janikiewicz, J.; Hanzelka, K.; Kozinski, K.; Kolczynska, K.; Dobrzyn, A. Islet β-cell failure in type
2 diabetes—Within the network of toxic lipids. Biochem. Biophys. Res. Commun. 2015, 460, 491–496.
[CrossRef] [PubMed]
7. Myers, S.A.; Nield, A.; Myers, M. Zinc Transporters, Mecahnisms of Action and Therapeutic Utility:
Implications for Type 2 Diabetes Mellitus. J. Nutr. Metab. 2012. [CrossRef]
8. Kambe, T.; Hashimoto, A.; Fujimoto, S. Current understanding of ZIP and ZnT zinc transporters in human
health and diseases. Cell. Mol. Life Sci. 2014, 71, 3281–3295. [CrossRef]
9. Kambe, T.; Tsuji, T.; Hashimoto, A.; Itsumura, N. The physiological, biochemical, and molecular roles of zinc
transporters in zinc homeostasis and metabolism. Physiol. Rev. 2015, 95, 749–784. [CrossRef]
10. Cousins, R.J.; Liuzzi, J.P.; Lichten, L.A. Mammalian zinc transport, trafficking, and signals. JBC 2006, 281,
24085–24089. [CrossRef]
11. Taylor, K.M.; Hiscox, S.; Nicholson, R.I.; Hogstrand, C.; Kille, P. Protein kinase CK2 triggers cytosolic zinc
signaling pathways by phosphorylation of zinc channel ZIP7. Sci. Signal. 2012, 5, ra11. [CrossRef] [PubMed]
12. Hogstrand, C.; Kille, P.; Nicholson, R.I.; Taylor, K.M. Zinc transporters and cancer: A potential role for ZIP7
as a hub for tyrosine kinase activation. Trends Mol. Med. 2009, 15, 101–111. [CrossRef] [PubMed]
13. Woodruff, G.; Bouwkamp, C.G.; de Vrij, F.M.; Lovenberg, T.; Bonaventure, P.; Kushner, S.A.; Harrington, A.W.
The Zinc Transporter SLC39A7 (ZIP7) Is Essential for Regulation of Cytosolic Zinc Levels. Mol. Pharm. 2018,
94, 1092–1100. [CrossRef] [PubMed]
14. Taylor, K.M.; Vichova, P.; Jordan, N.; Hiscox, S.; Hendley, R.; Nicholson, R.I. ZIP7-Mediated Intracellular
Zinc Transport Contributes to Aberrant Growth Factor Signaling in Antihormone-Resistant Breast Cancer
Cells. Endocrinology 2008, 149, 4912–4920. [CrossRef] [PubMed]
15. Myers, S.A.; Nield, A.; Chew, G.S.; Myers, M.A. The zinc transporter, Slc39a7 (Zip7) is implicated in glycaemic
control in skeletal muscle cells. PLoS ONE 2013, 8, e79316. [CrossRef]
16. Tuncay, E.; Bitirim, V.C.; Durak, A.; Carrat, G.R.J.; Taylor, K.M.; Rutter, G.A.; Turan, B. Hyperglycemia-Induced
Changes in ZIP7 and ZnT7 Expression Cause Zn(2+) Release From the Sarco(endo)plasmic Reticulum and
Mediate ER Stress in the Heart. Diabetes 2017, 66, 1346–1358. [CrossRef]
Cells 2019, 8, 663 17 of 19
17. Norouzi, S.; Adulcikas, J.; Sohal, S.S.; Myers, S. Zinc stimulates glucose oxidation and glycemic control by
modulating the insulin signaling pathway in human and mouse skeletal muscle cell lines. PLoS ONE 2018,
13, e0191727. [CrossRef]
18. Marshall, J.P.S.; Estevez, E.; Kammoun, H.L.; King, E.J.; Bruce, C.R.; Drew, B.G.; Qian, H.; Iliades, P.;
Gregorevic, P.; Febbraio, M.A.; et al. Skeletal muscle-specific overexpression of heat shock protein 72 improves
skeletal muscle insulin-stimulated glucose uptake but does not alter whole body metabolism. Diabetes Obes.
Metab. 2018, 20, 1928–1936. [CrossRef]
19. Yang, M.; Wei, D.; Mo, C.; Zhang, J.; Wang, X.; Han, X.; Wang, Z.; Xiao, H. Saturated fatty acid
palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression
of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis. 2013, 12, 104. [CrossRef]
20. Bellomo, E.A.; Meur, G.; Rutter, G.A. Glucose Regulates Free Cytosolic Zn2+ Concentration, Slc39 (ZiP), and
Metallothionein Gene Expression in Primary Pancreatic Islet β-Cells. J. Biol. Chem. 2011, 286, 25778–25789.
[CrossRef]
21. Feng, X.T.; Wang, T.Z.; Leng, J.; Chen, Y.; Liu, J.B.; Liu, Y.; Wang, W.J. Palmitate contributes to insulin
resistance through downregulation of the Src-mediated phosphorylation of Akt in C2C12 myotubes. Biosci.
Biotechnol. Biochem. 2012, 76, 1356–1361. [CrossRef] [PubMed]
22. Nakamura, S.; Takamura, T.; Matsuzawa-Nagata, N.; Takayama, H.; Misu, H.; Noda, H.; Nabemoto, S.;
Kurita, S.; Ota, T.; Ando, H.; et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through
reactive oxygen species produced by mitochondria. J. Biol. Chem. 2009, 284, 14809–14818. [CrossRef]
[PubMed]
23. Taylor, R. Insulin Resistance and Type 2 Diabetes. Diabetes 2012, 61, 778–779. [CrossRef] [PubMed]
24. Bevan, P. Insulin signalling. J. Cell Sci. 2001, 114, 1429–1430. [PubMed]
25. Tokarz, V.L.; MacDonald, P.E.; Klip, A. The cell biology of systemic insulin function. J. Cell Biol. 2018.
[CrossRef] [PubMed]
26. Wu, Y.; Lu, H.; Yang, H.; Li, C.; Sang, Q.; Liu, X.; Liu, Y.; Wang, Y.; Sun, Z. Zinc stimulates glucose consumption
by modulating the insulin signaling pathway in L6 myotubes: Essential roles of Akt–GLUT4, GSK3β and
mTOR–S6K1. J. Nutr. Biochem. 2016, 34, 126–135. [CrossRef]
27. Hardy, A.B.; Wijesekara, N.; Genkin, I.; Prentice, K.J.; Bhattacharjee, A.; Kong, D.; Chimienti, F.; Wheeler, M.B.
Effects of high-fat diet feeding on Znt8-null mice: Differences between beta-cell and global knockout of Znt8.
Am. J. Physiol. Endocrinol. Metab. 2012, 302, E1084–E1096. [CrossRef]
28. Fukunaka, A.; Fukada, T.; Bhin, J.; Suzuki, L.; Tsuzuki, T.; Takamine, Y.; Bin, B.-H.; Yoshihara, T.;
Ichinoseki-Sekine, N.; Naito, H.; et al. Zinc transporter ZIP13 suppresses beige adipocyte biogenesis
and energy expenditure by regulating C/EBP-β expression. PLoS Genet. 2017, 13, e1006950. [CrossRef]
29. Liu, Y.; Batchuluun, B.; Ho, L.; Zhu, D.; Prentice, K.J.; Bhattacharjee, A.; Zhang, M.; Pourasgari, F.; Hardy, A.B.;
Taylor, K.M. Characterization of Zinc Influx Transporters (ZIPs) in Pancreatic β Cells Roles in Regulating
Cytosolic Zinc Homeostasis and Insulin Secretion. J. Biol. Chem. 2015, 290, 18757–18769. [CrossRef]
30. Jewell, J.L.; Oh, E.; Ramalingam, L.; Kalwat, M.A.; Tagliabracci, V.S.; Tackett, L.; Elmendorf, J.S.;
Thurmond, D.C. Munc18c phosphorylation by the insulin receptor links cell signaling directly to SNARE
exocytosis. J. Cell Biol. 2011, 193, 185–199. [CrossRef]
31. Song, E.K.; Lee, Y.R.; Kim, Y.R.; Yeom, J.H.; Yoo, C.H.; Kim, H.K.; Park, H.M.; Kang, H.S.; Kim, J.S.; Kim, U.H.;
et al. NAADP mediates insulin-stimulated glucose uptake and insulin sensitization by PPARgamma in
adipocytes. Cell Rep. 2012, 2, 1607–1619. [CrossRef] [PubMed]
32. Zacherl, J.R.; Tourkova, I.; St Croix, C.M.; Robinson, L.J.; Peck Palmer, O.M.; Mihalik, S.J.; Blair, H.C. Elaidate,
an 18-carbon trans-monoenoic fatty acid, but not physiological fatty acids increases intracellular Zn(2+) in
human macrophages. J. Cell. Biochem. 2015, 116, 524–532. [CrossRef] [PubMed]
33. Ding, L.; Zhang, L.; Biswas, S.; Schugar, R.C.; Brown, J.M.; Byzova, T.; Podrez, E. Akt3 inhibits adipogenesis
and protects from diet-induced obesity via WNK1/SGK1 signaling. JCI Insight 2017, 2, e95687. [CrossRef]
[PubMed]
Cells 2019, 8, 663 18 of 19
34. Brozinick, J.T.; Roberts, B.R.; Dohm, G.L. Defective Signaling Through Akt-2 and -3 but Not Akt-1 in
Insulin-Resistant Human Skeletal Muscle. Potential Role Insul. Resist. 2003, 52, 935–941.
35. Brown, D.M.; Williams, H.; Ryan, K.J.; Wilson, T.L.; Daniel, Z.C.; Mareko, M.H.; Emes, R.D.; Harris, D.W.;
Jones, S.; Wattis, J.A.; et al. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) and serine
biosynthetic pathway genes are co-ordinately increased during anabolic agent-induced skeletal muscle
growth. Sci. Rep. 2016, 6, 28693. [CrossRef] [PubMed]
36. Verma, N.K.; Singh, J.; Dey, C.S. PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal
muscle cells. Br. J. Pharmacol. 2004, 143, 1006–1013. [CrossRef] [PubMed]
37. Miles, P.D.; Barak, Y.; He, W.; Evans, R.M.; Olefsky, J.M. Improved insulin-sensitivity in mice heterozygous
for PPAR-gamma deficiency. J. Clin. Investig. 2000, 105, 287–292. [CrossRef] [PubMed]
38. Yamauchi, T.; Kamon, J.; Waki, H.; Murakami, K.; Motojima, K.; Komeda, K.; Ide, T.; Kubota, N.; Terauchi, Y.;
Tobe, K.; et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor
gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 2001,
276, 41245–41254. [CrossRef]
39. Sun, Q.; Li, Q.; Zhong, W.; Zhang, J.; Sun, X.; Tan, X.; Yin, X.; Sun, X.; Zhang, X.; Zhou, Z. Dysregulation
of hepatic zinc transporters in a mouse model of alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver
Physiol. 2014, 307, G313–G322. [CrossRef]
40. Singh, J.; Verma, N.K.; Kansagra, S.M.; Kate, B.N.; Dey, C.S. Altered PPARgamma expression inhibits
myogenic differentiation in C2C12 skeletal muscle cells. Mol. Cell. Biochem. 2007, 294, 163–171. [CrossRef]
41. Mnatsakanyan, H.; i Serra, R.S.; Rico, P.; Salmerón-Sánchez, M. Zinc uptake promotes myoblast differentiation
via Zip7 transporter and activation of Akt signalling transduction pathway. Sci. Rep. 2018, 8, 13642. [CrossRef]
[PubMed]
42. Shinohara, H.; Inoue, A.; Toyama-Sorimachi, N.; Nagai, Y.; Yasuda, T.; Suzuki, H.; Horai, R.; Iwakura, Y.;
Yamamoto, T.; Karasuyama, H.; et al. Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced
signaling. J. Exp. Med. 2005, 201, 333–339. [CrossRef] [PubMed]
43. Yasuda, T.; Shirakata, M.; Iwama, A.; Ishii, A.; Ebihara, Y.; Osawa, M.; Honda, K.; Shinohara, H.; Sudo, K.;
Tsuji, K.; et al. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J. Exp. Med.
2004, 200, 1681–1687. [CrossRef] [PubMed]
44. Huang, S.M.; Hancock, M.K.; Pitman, J.L.; Orth, A.P.; Gekakis, N. Negative regulators of insulin signaling
revealed in a genome-wide functional screen. PLoS ONE 2009, 4, e6871. [CrossRef] [PubMed]
45. Tu, Y.C.; Huang, D.Y.; Shiah, S.G.; Wang, J.S.; Lin, W.W. Regulation of c-Fos gene expression by NF-kappaB:
A p65 homodimer binding site in mouse embryonic fibroblasts but not human HEK293 cells. PLoS ONE
2013, 8, e84062. [CrossRef]
46. Delghandi, M.P.; Johannessen, M.; Moens, U. The cAMP signalling pathway activates CREB through PKA,
p38 and MSK1 in NIH 3T3 cells. Cell Signal. 2005, 17, 1343–1351. [CrossRef] [PubMed]
47. Hojyo, S.; Fukada, T.; Shimoda, S.; Ohashi, W.; Bin, B.H.; Koseki, H.; Hirano, T. The zinc transporter
SLC39A14/ZIP14 controls G-protein coupled receptor-mediated signaling required for systemic growth.
PLoS ONE 2011, 6, e18059. [CrossRef]
48. Yan, G.; Zhang, Y.; Yu, J.; Yu, Y.; Zhang, F.; Zhang, Z.; Wu, A.; Yan, X.; Zhou, Y.; Wang, F. Slc39a7/zip7 plays
a critical role in development and zinc homeostasis in zebrafish. PLoS ONE 2012, 7, e42939. [CrossRef]
49. Fukada, T.; Yamasaki, S.; Nishida, K.; Murakami, M.; Hirano, T. Zinc homeostasis and signaling in health
and diseases. J. Biol. Inorg. Chem. 2011, 16, 1123–1134. [CrossRef]
50. Castellano, E.; Santos, E. Functional specificity of ras isoforms: So similar but so different. Genes Cancer 2011,
2, 216–231. [CrossRef]
51. Klein, C.; Creach, K.; Irintcheva, V.; Hughes, K.J.; Blackwell, P.L.; Corbett, J.A.; Baldassare, J.J. Zinc induces
ERK-dependent cell death through a specific Ras isoform. Apoptosis Int. J. Program. Cell Death 2006, 11,
1933–1944. [CrossRef] [PubMed]
52. Hennigar, S.R.; Velasquez, V.; Kelleher, S.L. Obesity-Induced Inflammation Is Associated with Alterations in
Subcellular Zinc Pools and Premature Mammary Gland Involution in Lactating Mice. J. Nutr. 2015, 145,
1999–2005. [CrossRef] [PubMed]
53. Tinkov, A.A.; Popova, E.V.; Gatiatulina, E.R.; Skalnaya, A.A.; Yakovenko, E.N.; Alchinova, I.B.; Karganov, M.Y.;
Skalny, A.V.; Nikonorov, A.A. Decreased adipose tissue zinc content is associated with metabolic parameters
in high fat fed Wistar rats. Acta Sci. Pol. Technol. Aliment. 2016, 15, 99–105. [CrossRef] [PubMed]
Cells 2019, 8, 663 19 of 19
54. Cooper-Capetini, V.; de Vasconcelos, D.A.A.; Martins, A.R.; Hirabara, S.M.; Donato, J., Jr.; Carpinelli, A.R.;
Abdulkader, F. Zinc Supplementation Improves Glucose Homeostasis in High Fat-Fed Mice by Enhancing
Pancreatic beta-Cell Function. Nutrients 2017, 9, 1150. [CrossRef] [PubMed]
55. Liu, M.J.; Bao, S.; Bolin, E.R.; Burris, D.L.; Xu, X.; Sun, Q.; Killilea, D.W.; Shen, Q.; Ziouzenkova, O.;
Belury, M.A.; et al. Zinc deficiency augments leptin production and exacerbates macrophage infiltration into
adipose tissue in mice fed a high-fat diet. J. Nutr. 2013, 143, 1036–1045. [CrossRef] [PubMed]
56. Di Martino, G.; Matera, M.G.; De Martino, B.; Vacca, C.; Di Martino, S.; Rossi, F. Relationship between zinc
and obesity. J. Med. 1993, 24, 177–183. [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
